Lumicitabine

N/A

Report date: 2025/04/20 20:00:03
NME

Base Information

Drug NameLumicitabine
Drug Alias NameJNJ-1575ALS-8176AL-8176JNJ-64041575ALS-008176
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRNA-directed RNA polymerase L inhibitors
TargetsRNA-directed RNA polymerase L
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[28] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen-Cilag International NvAlios Biopharma IncJanssen Pharmaceutical Kk +[5] 
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A